Skip to content

Acceptability and Efficacy of Zemedy App Versus Education and Relaxation Training App for IBS

Acceptability and Efficacy of Zemedy App Versus Education and Relaxation Training App for IBS

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04665271
Enrollment
453
Registered
2020-12-11
Start date
2021-03-01
Completion date
2024-05-28
Last updated
2025-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable Bowel Syndrome

Keywords

cognitive behavioral therapy

Brief summary

The purpose of this research is to assess if a new digital app version of a self-help intervention for Irritable Bowel Syndrome (IBS), is an acceptable and effective treatment for improving the overall quality of life in patients with IBS.

Detailed description

The aim of the current study is to test the acceptability and efficacy of an updated digital app for IBS patients. The design of the study is experimental. There will be two experimental groups, an immediate treatment group and an active control group. Once consented and enrolled, participants will be randomly assigned to either the immediate treatment group or the active control group by the coin toss feature of random.org. Participants in the immediate treatment group will be able to download the app at no cost. Participants in the control group will be given access to an education and relaxation training control app at no cost to them. At 8 weeks after enrollment, all participants in both groups will receive a battery of follow-up questionnaires (the same that they answered directly after consenting in the beginning of the study as baseline measures). Upon receipt of the 8 week questionnaire data, participants in the control group will be given access to the Zemedy app. After having had access to the app for 8 weeks, control participants will be asked to complete another set of questionnaires. All participants will receive 3 month post-treatment follow-up questionnaires. The research method is experimental, cross over (randomized controlled trial) with a control control. Participation in the study will last approximately 4.5 months, depending on the subjects willingness to participate and rate of completion.

Interventions

BEHAVIORALZemedy App

Digital smart phone app that delivers cognitive-behavioral therapy for IBS

Sponsors

Bold Health Inc.
CollaboratorINDUSTRY
University of Pennsylvania
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

Active control with cross-over at post-treatment and three month follow-up

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Self-report of physician diagnosis of IBS. * At least 18 years of age.

Exclusion criteria

* Severe depression or suicidality * Comorbid GI disorder such as inflammatory bowel disease or celiac disease. * Pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Irritable Bowel Syndrome Quality of Life (IBSQoL)8 weeksIBS specific health related quality of life measure. Scale scores range from 0-100 with higher scores reflecting more impairment (worse outcome)
Gastrointestinal Symptom Rating Scale (GSRS)8 weeksGastrointestinal Symptom Rating Scale. Scale scores range from 0-78 with high scores representing worse GI symptoms.

Secondary

MeasureTime frameDescription
Fear of Food Questionnaire (FFQ)8 weeksScale measures fear of food and aversive consequences of eating. Scale scores range from 0-90 with higher scores representing more fear and impairment.
GI-Cognitions Questionnaire (GICog)8 weeksScale measures distorted, catastrophic beliefs about the social and occupational implications of having gastrointestinal symptoms. Scale scores range from 0 to 64 with higher scores representing worse outcomes (more distorted, catastrophic beliefs about GI symptoms)
Work Productivity and Activity Impairment (WPAI)8 weeksMeasures occupational impairment stemming from a health condition. scores range from 0 to 30 with higher scores representing more impairment
Beck Depression Inventory (BDI)8 weeksMeasures depressive symptoms. Scale scores range from 0 to 63 with higher scores representing more severe depressive symptoms.
Visceral Sensitivity Index (VSI)8 weeksScale measures anxiety about visceral (gut) sensations. Scale scores range from 0 to 75 with higher scores representing more anxiety.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 22, 2026